Phase 3 Study of Roflumilast Cream 0.3% Shows Promise for Plaque Psoriasis
A Phase 3 study is underway to assess the efficacy and safety of roflumilast cream 0.3% in patients with plaque psoriasis.
Phase III
Dermatology / Psoriasis
Status
Active
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase 3 study of roflumilast cream 0.3% is significant as it could introduce a new competitive treatment option in the psoriasis market, particularly in China. Success in this trial may strengthen Hangzhou Zhongmei Huadong Pharmaceutical's position in dermatology and influence market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any subsequent regulatory submissions or approvals for roflumilast cream.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.